Anti-diabetic potential of Urtica Dioica: current knowledge and future direction

2022 ◽  
Author(s):  
Anita Chehri ◽  
Reza Yarani ◽  
Zahra Yousefi ◽  
Tannaz Novin Bahador ◽  
Seyed Kazem Shakouri ◽  
...  
Keyword(s):  
Current Knowledge ◽  
Urtica Dioica ◽  
Future Direction

scholarly journals Therapeutic Perspectives of Molecules from Urtica dioica Extracts for Cancer Treatment

Molecules ◽  
2019 ◽  
Vol 24 (15) ◽  
pp. 2753 ◽  
Author(s):  
Sabrina Esposito ◽  
Alessandro Bianco ◽  
Rosita Russo ◽  
Antimo Di Maro ◽  
Carla Isernia ◽  
...  
Keyword(s):  
Natural Products ◽  
Cancer Cells ◽  
Current Knowledge ◽  
Biological Activities ◽  
Urtica Dioica ◽  
Cancer Therapies ◽  
Edible Plant ◽  
Bioactive Natural Products ◽  
Human Cancers ◽  
Anti Cancer

A large range of chronic and degenerative diseases can be prevented through the use of food products and food bioactives. This study reports the health benefits and biological activities of the Urtica dioica (U. dioica) edible plant, with particular focus on its cancer chemopreventive potential. Numerous studies have attempted to investigate the most efficient anti-cancer therapy with few side effects and high toxicity on cancer cells to overcome the chemoresistance of cancer cells and the adverse effects of current therapies. In this regard, natural products from edible plants have been assessed as sources of anti-cancer agents. In this article, we review current knowledge from studies that have examined the cytotoxic, anti-tumor and anti-metastatic effects of U. dioica plant on several human cancers. Special attention has been dedicated to the treatment of breast cancer, the most prevalent cancer among women and one of the main causes of death worldwide. The anti-proliferative and apoptotic effects of U. dioica have been demonstrated on different human cancers, investigating the properties of U. dioica at cellular and molecular levels. The potent cytotoxicity and anti-cancer activity of the U. dioica extracts are due to its bioactive natural products content, including polyphenols which reportedly possess anti-oxidant, anti-mutagenic and anti-proliferative properties. The efficacy of this edible plant to prevent or mitigate human cancers has been demonstrated in laboratory conditions as well as in experimental animal models, paving the way to the development of nutraceuticals for new anti-cancer therapies.

Laser Welding of Titanium and its Alloys for Medical Applications: Current Knowledge and Future Direction

2009 ◽  
Vol 618-619 ◽  
pp. 291-294 ◽  
Author(s):  
Alexander Buddery ◽  
Matthew S. Dargusch ◽  
David H. StJohn ◽  
John Drennan ◽  
Samih Nabulsi
Keyword(s):  
Laser Welding ◽  
Current Knowledge ◽  
Medical Applications ◽  
Current State ◽  
State Of Research ◽  
Future Direction

This paper outlines the current state of research into laser welding of titanium and its alloys for medical applications. The differences that exist between the medical and other industries are described and a direction for advancing research in this field is proposed.

scholarly journals Controlled Drug Delivery Vehicles in Veterinary Oncology: State-of-the-Art and Future Directions

Processes ◽  
2020 ◽  
Vol 8 (5) ◽  
pp. 541 ◽  
Author(s):  
Patricia de Faria Lainetti ◽  
Fernanda Zuliani ◽  
Antonio Fernando Leis-Filho ◽  
Ricardo Henrique Fonseca Alves ◽  
Carlos Eduardo Fonseca-Alves
Keyword(s):  
Drug Delivery ◽  
Anticancer Agents ◽  
Kinase Inhibitors ◽  
Current Knowledge ◽  
Controlled Drug Delivery ◽  
Chemotherapeutic Agents ◽  
Drug Delivery Vehicles ◽  
Controlled Systems ◽  
Delivery Vehicles ◽  
Future Direction

Controlled drug delivery systems can be used to carry several anticancer agents, including classical chemotherapeutic agents such as doxorubicin, paclitaxel or cisplatin, and are also used for the encapsulation of tyrosine kinase inhibitors and monoclonal antibodies. Usually, the controlled systems are used to decrease drug toxicity, increase local drug concentration or target specific organs or systems. In dogs, liposomal doxorubicin is the most known controlled drug delivery vehicle in veterinary medicine. However, several antitumor drugs can be encapsulated within these systems. Since the delivery vehicles are a relatively new topic in veterinary oncology, this review aims to discuss the current knowledge regarding the controlled drug delivery vehicles and discuss the current challenges and future direction of its use in veterinary oncology.

scholarly journals An Overview of Preoperative Glucose Evaluation, Management, and Perioperative Impact

2009 ◽  
Vol 3 (6) ◽  
pp. 1261-1269 ◽  
Author(s):  
Ann M. Sheehy ◽  
Robert A. Gabbay
Keyword(s):  
Glycemic Control ◽  
Practice Guidelines ◽  
Current Knowledge ◽  
Tight Glycemic Control ◽  
Prior History ◽  
Optimal Care ◽  
History Of ◽  
Glycemic Targets ◽  
Future Direction ◽  
National Practice

Perioperative hyperglycemia is a common phenomenon affecting patients both with and without a known prior history of diabetes. Despite an exponential rise in publications and studies of inpatient hyperglycemia over the last decade, many questions still exist as to what defines optimal care of these patients. Initial enthusiasm for tight glycemic control has waned as the unanticipated reality of hypoglycemia and mortality has been realized in some prospective studies. The recent dramatic modification of national practice guidelines to endorse more modest inpatient glycemic targets highlights the dynamic nature of current knowledge as the next decade approaches. This review discusses perioperative hyperglycemia and the categories of patients affected by it. It reviews current recommendations for ambulatory diabetes screening and its importance in preoperative patient care. Finally, it concludes with a review of current practice guidelines, as well as a discussion of future direction and goals for inpatient perioperative glycemic control.

scholarly journals Current knowledge and future direction of research on soy isoflavones as a therapeutic agents

2010 ◽  
Vol 4 (8) ◽  
pp. 111 ◽  
Author(s):  
V Kalaiselvan ◽  
M Kalaivani ◽  
A Vijayakumar ◽  
K Sureshkumar ◽  
K Venkateskumar
Keyword(s):  
Current Knowledge ◽  
Therapeutic Agents ◽  
Soy Isoflavones ◽  
Future Direction

scholarly journals Microalgae as Contributors to Produce Biopolymers

Marine Drugs ◽  
2021 ◽  
Vol 19 (8) ◽  
pp. 466
Author(s):  
Rozita Madadi ◽  
Hamid Maljaee ◽  
Luísa S. Serafim ◽  
Sónia P. M. Ventura
Keyword(s):  
Food Packaging ◽  
Current Knowledge ◽  
Polymeric Materials ◽  
Current Review ◽  
Cultivation Process ◽  
Biological Sources ◽  
Living Organisms ◽  
Future Direction ◽  
Insight Into ◽  
Microalgae Growth

Biopolymers are very favorable materials produced by living organisms, with interesting properties such as biodegradability, renewability, and biocompatibility. Biopolymers have been recently considered to compete with fossil-based polymeric materials, which rase several environmental concerns. Biobased plastics are receiving growing interest for many applications including electronics, medical devices, food packaging, and energy. Biopolymers can be produced from biological sources such as plants, animals, agricultural wastes, and microbes. Studies suggest that microalgae and cyanobacteria are two of the promising sources of polyhydroxyalkanoates (PHAs), cellulose, carbohydrates (particularly starch), and proteins, as the major components of microalgae (and of certain cyanobacteria) for producing bioplastics. This review aims to summarize the potential of microalgal PHAs, polysaccharides, and proteins for bioplastic production. The findings of this review give insight into current knowledge and future direction in microalgal-based bioplastic production considering a circular economy approach. The current review is divided into three main topics, namely (i) the analysis of the main types and properties of bioplastic monomers, blends, and composites; (ii) the cultivation process to optimize the microalgae growth and accumulation of important biobased compounds to produce bioplastics; and (iii) a critical analysis of the future perspectives on the field.

Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction

2017 ◽  
Vol 197 (2) ◽  
pp. 287-295 ◽  
Author(s):  
Grant P. Redrow ◽  
Charles C. Guo ◽  
Maurizio A. Brausi ◽  
Jonathan A. Coleman ◽  
Mario I. Fernandez ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Current Knowledge ◽  
Upper Urinary Tract ◽  
Future Direction ◽  
Upper Urinary Tract Carcinoma

scholarly journals Non-Invasive Assessment of Pulmonary Vascular Resistance in Pulmonary Hypertension: Current Knowledge and Future Direction

2017 ◽  
Vol 26 (4) ◽  
pp. 323-330 ◽  
Author(s):  
Pyi Naing ◽  
Harveen Kuppusamy ◽  
Gregory Scalia ◽  
Graham S. Hillis ◽  
David Playford
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Vascular Resistance ◽  
Vascular Resistance ◽  
Current Knowledge ◽  
Non Invasive ◽  
Future Direction

Stem cells for lupus nephritis: a concise review of current knowledge

Lupus ◽  
2018 ◽  
Vol 27 (12) ◽  
pp. 1881-1897 ◽  
Author(s):  
P D Sattwika ◽  
R Mustafa ◽  
A Paramaiswari ◽  
E H Herningtyas
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Lupus Nephritis ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Lupus Erythematosus ◽  
Current Knowledge ◽  
Secondary Effects ◽  
Hematopoietic Stem ◽  
Future Direction

Lupus nephritis (LN), a common manifestation of systemic lupus erythematosus (SLE), accounts for significant morbidity and mortality in SLE patients. Since the available standard therapies and biologic agents for LN are yet to achieve the desired response and have considerable secondary effects, stem cell therapy has now emerged as a new approach. This therapy involves the transplantation of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). Our current review will highlight the progress of stem cell therapy for LN, along with the challenges encountered and the future direction of this approach.

Sign in / Sign up

Export Citation Format

Share Document